Choice of first line systemic treatment in pancreatic cancer among national experts

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.7K citations

Medicine, Oncology, Pharmacology +13

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

Jacques Ferlay, Eva Steliarova‐Foucher, Joannie Lortet‐Tieulent et al. · European Journal of Cancer · 2013 · 5.2K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.9K citations

Medicine, Oncology, Pharmacology +17

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud M. Al-Hawary et al. · Journal of the National Comprehensive Cancer Network · 2017 · 1K citations

Medicine, Oncology, Surgery +17